Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1844 - Effect of lateral lymph node dissection for lower rectal cancer: An ad hoc analysis of the ACTS-RC randomized clinical trial


09 Sep 2017


Poster display session


Surgical Oncology;  Radiation Oncology;  Colon and Rectal Cancer


Eiji Oki


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


E. Oki1, M. Shimokawa2, A. Murata3, T. Takahashi4, K. Maeda5, T. Kusumoto6, Y. Munemoto7, K. Ando1, R. Nakanishi1, M. Sugiyama1, Y. Nakashima1, H. Saeki1, S. Saji8, Y. Maehara1

Author affiliations

  • 1 Surgery And Science, Kyushu University Hospital, 812-8582 - FUKUOKA/JP
  • 2 Clinical Research Institute, National Kyushu Cancer Center, 811-1395 - Fukuoka/JP
  • 3 Department Of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Aomori/JP
  • 4 Department Of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu/JP
  • 5 Surgical Oncology, Osaka City University, Osaka/JP
  • 6 Department Of Surgery, Gastrointestinal Center, National Hospital Organization Kyushu Medical Center, FUKUOKA/JP
  • 7 Department Of Surgery, Fukui-ken Saiseikai Hospital, Fukui/JP
  • 8 Chairman, Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo/JP


Abstract 1844


The phase III ACTS-RC (Adjuvant Chemotherapy for Stage II/III Rectal Cancer) trial showed benefits in relapse-free survival (RFS) in rectal cancer with tegafur, 5-chloro-2,4-dihydropyrimidine, and potassium oxonate (S-1) adjuvant chemotherapy in comparison with uracil and tegafur (UFT) therapy. Lateral lymph node dissection (LLND) has been one of the standard treatments for lower rectal cancer patients in Japan. However, it has been debated whether LLND has survival benefits. The aim of this study was to evaluate the impact of lateral LLND on the outcomes in the ACTS-RC randomized clinical trial.


In a total of 445 lower rectal cancer cases (Stage I/II/IIIA/IIIB/IIIC: 1/130/10/59/165/80) from 959 rectal cancer cases in the ACTS-RC trial, 215 underwent LLND and 230 did not. UFT and S-1 therapy was prescribed for 110 and 105 patients with LLND, respectively, and for 111 and 119 patients without LLND, respectively.


There were no significant differences in patient background characteristics, except for age and pathological T stage, between the LLND and without-LLND groups. Younger patients were often selected as candidates for LLND, and LLND had no impact on RFS or overall survival (OS) in all patients with lower rectal cancer (hazard ratio [HR]=0.941, 95% confidence interval [CI]: 0.696–1.271). In Stage IIIB/C patients, LLND improved the RFS (HR = 0.762, 95% CI: 0.533–1.091). This trend was the same in both the S-1 (HR = 0.766, 95% CI: 0.449–1.306) and UFT arms (HR = 0.790, 95% CI: 0.487–1.283), despite the better RFS in the S-1 arm than in the UFT arm. LLND did not show a major impact on OS in Stage IIIB/C patients.


This exploratory analysis showed that LLND improves RFS in patients receiving either UFT or S-1 therapy, although the results were not significant. LLND has an additional impact on improving RFS of patients with lower rectal cancer undergoing adjuvant chemotherapy.

Clinical trial identification

UMIN-CTR (C000000385)

Legal entity responsible for the study

Japanese foudation for multidiscipilinary treatment of cancer




E. Oki: Honoraria for lecturing from Taiho Pharmaceutical Co., Ltd.; Yakult Honsha Co., Ltd.; and Chugai Pharmaceutical Co., Ltd. Y. Maehara: Honoraria for lecturing from Taiho Pharmaceutical Co., Ltd.; Yakult Honsha Co., Ltd.; and Chugai Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.